Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Renaissance Acquisition Holdings LLC, GlaxoSmithKline sales and marketing update

GlaxoSmithKline granted Renaissance rights to market six approved dermatology drugs and three formulations of Zovirax acyclovir in the U.S. The dermatology products are Evoclin

Read the full 241 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE